Relief Therapeutics Holding (Relief Therapeutics Holding) Cash And Cash Equivalents : $16.83 Mil (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding Cash And Cash Equivalents?

Relief Therapeutics Holding's quarterly cash and cash equivalents declined from Dec. 2022 ($20.65 Mil) to Jun. 2023 ($14.21 Mil) but then increased from Jun. 2023 ($14.21 Mil) to Dec. 2023 ($16.83 Mil).

Relief Therapeutics Holding's annual cash and cash equivalents declined from Dec. 2021 ($48.60 Mil) to Dec. 2022 ($20.65 Mil) and declined from Dec. 2022 ($20.65 Mil) to Dec. 2023 ($16.83 Mil).

Relief Therapeutics Holding Cash And Cash Equivalents Historical Data

The historical data trend for Relief Therapeutics Holding's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Cash And Cash Equivalents Chart

Relief Therapeutics Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.13

42.84

48.60

20.65

16.83

Relief Therapeutics Holding Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															48.60	30.79	20.65	14.21	16.83

Relief Therapeutics Holding Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Relief Therapeutics Holding (OTCPK:RLFTF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Relief Therapeutics Holding Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK RLF:Switzerland

Address

Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.